微创心输出量监测指导萘甲唑啉中毒救治一例
本文报告一例32岁抑郁男性摄入含0.1%萘甲唑啉的消毒液150 mL(相当于萘甲唑啉150 mg),5小时后入院,表现为心动过缓(46次/分)、血压166/122 mmHg和外周发绀。使用FloTrac/EV1000微创心输出量监测系统监测全身血管阻力,入院时全身血管阻力指数(SVRI)升高至4457 dyne.s/cm5/m2(正常范围1970-2390 dyne.s/cm5/m2),初始持续静脉输注酚妥拉明后2小时内SVRI恢复正常。随后以维持SVRI正常为目标开始持续输注尼卡地平,治疗开始后10小时尼卡地平剂量达峰值9 mg/h(1.9 μg/kg/min),8小时后停药,第4天出院无后遗症。作者认为,用微创心输出量监测系统追踪血管阻力可有效指导萘甲唑啉中毒时酚妥拉明或尼卡地平的剂量调整。
要点
- 32岁男性摄入150 mL含0.1%萘甲唑啉消毒液(相当于150 mg),5小时后出现心动过缓46次/分、血压166/122 mmHg、外周发绀。
- 入院时SVRI 4457 dyne.s/cm5/m2(正常1970-2390 dyne.s/cm5/m2),持续静脉输注酚妥拉明后2小时内SVRI恢复正常。
- 随后以维持SVRI正常为目标持续输注尼卡地平,治疗开始后10小时剂量达峰值9 mg/h(1.9 μg/kg/min),8小时后停药。
- 第4天出院无后遗症;作者认为微创心输出量监测追踪血管阻力可有效指导酚妥拉明或尼卡地平剂量。
- 原文指出萘甲唑啉中毒目前尚无公认的酚妥拉明或尼卡地平给药方案。
适用人群与场景
- 摄入含萘甲唑啉的鼻喷雾、滴眼液或非处方消毒剂后出现中毒表现的急诊患者
- 本例为32岁抑郁男性,摄入150 mL含0.1%萘甲唑啉的消毒剂(相当于150 mg萘甲唑啉)
诊断标准与关键阈值
- 萘甲唑啉中毒的临床征象包括心动过缓(本例46次/分)、血压升高(本例166/122 mmHg)和外周发绀
- SVRI正常范围1970-2390 dyne.s/cm5/m2;本例入院时SVRI 4457 dyne.s/cm5/m2,提示升高
处置流程与药物剂量
- 使用FloTrac™/EV1000™系统(Edwards Lifesciences,Irvine,CA,USA)微创心输出量监测系统监测全身血管阻力
- 初始给予酚妥拉明持续静脉输注,2小时内SVRI恢复正常
- 随后以维持SVRI正常为目标开始尼卡地平持续输注,治疗开始后10小时剂量达峰值9 mg/h(1.9 μg/kg/min),8小时后停药
红旗征与不能漏的情况
- 摄入萘甲唑啉后出现心动过缓、血压显著升高和外周发绀,提示中毒及后负荷增加
- 萘甲唑啉中毒可因外周动脉收缩增加后负荷,导致多器官衰竭等并发症
研究设计与关键结果
- 病例报告:32岁男性摄入150 mL含0.1%萘甲唑啉消毒液(相当于150 mg),5小时后入院,表现为心动过缓46次/分、血压166/122 mmHg、外周发绀
- 入院时SVRI 4457 dyne.s/cm5/m2(正常1970-2390 dyne.s/cm5/m2),酚妥拉明持续静脉输注后2小时内SVRI恢复正常
- 随后尼卡地平持续输注,治疗开始后10小时剂量达峰值9 mg/h(1.9 μg/kg/min),8小时后停药,第4天出院无后遗症
证据类型、等级与局限
- 证据类型:病例报告
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,使用微创心输出量监测系统追踪血管阻力可有效指导萘甲唑啉中毒时酚妥拉明或尼卡地平的剂量调整
- 原文指出萘甲唑啉中毒目前尚无公认的酚妥拉明或尼卡地平给药方案
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Naphazoline, a nonspecific alpha-adrenoceptor stimulant, is a potent vasoconstrictor used in nasal sprays, eye drops, and over-the-counter antiseptics. Naphazoline intoxication increases afterload by constricting the peripheral arteries, which can lead to complications including multiple organ failure. Although phentolamine, a nonselective alpha-adrenoceptor antagonist, and nicardipine, a calcium channel blocker, are used for the treatment of naphazoline intoxication, no established administration protocols currently exist. We present the case of a 32-year-old male with depression who ingested 150 mL of an antiseptic containing 0.1% naphazoline (equivalent to 150 mg of naphazoline). Five hours after ingestion, the patient was admitted to hospital exhibiting signs of naphazoline intoxication, such as bradycardia (46 beats/min), blood pressure of 166/122 mmHg, and peripheral cyanosis. We used the FloTrac™/EV1000™ system (Edwards Lifesciences, Irvine, CA, USA), a minimally invasive cardiac output monitoring system, to monitor systemic vascular resistance. The systemic vascular resistance index (SVRI) was elevated (4457 dyne.s/cm5/m2; nomal range: 1970-2390 dyne.s/cm5/m2) upon admission and initial treatment with continuous intravenous infusion of phentolamine led to SVRI normalization within 2 h. With the goal of maintaining SVRI normalization, continuous infusion with nicardipine was then started. At 10 h after treatment initiation, the nicardipine dose peaked at 9 mg/h (1.9 μg/kg/min). Treatment was discontinued 8 h later, and the patient was discharged on the fourth day without sequelae. In conclusion, the use of a minimally invasive cardiac output monitoring system to track vascular resistance can effectively guide the dosing of phentolamine or nicardipine in the treatment of naphazoline intoxication.
参考来源
- Oishi T, Kashiura M, Yasuda H, et al. Naphazoline intoxication managed with minimally invasive cardiac output monitoring. Am J Emerg Med. 2023. PMID: 38155033. doi:10.1016/j.ajem.2023.12.034
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。